• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Impinj Inc.
    $PI
    2/6/2026$112.00Outperform → In-line
    Evercore ISI
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    Impinj Inc.
    $PI
    11/7/2025$200.00Neutral
    UBS
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Impinj downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Impinj from Outperform to In-line and set a new price target of $112.00

    2/6/26 8:09:28 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Dian C

    4 - ARTESIAN RESOURCES CORP (0000863110) (Issuer)

    3/23/26 4:00:03 PM ET
    $ARTNA
    Water Supply
    Utilities

    SEC Form 4 filed by Taylor Dian C

    4 - ARTESIAN RESOURCES CORP (0000863110) (Issuer)

    3/20/26 4:32:55 PM ET
    $ARTNA
    Water Supply
    Utilities

    SEC Form 4 filed by Taylor Dian C

    4 - ARTESIAN RESOURCES CORP (0000863110) (Issuer)

    3/20/26 9:29:12 AM ET
    $ARTNA
    Water Supply
    Utilities

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots

    Early-stage deployments across multiple U.S. regions expected to support initial service revenue generation and scalable commercialization modelBEIJING, March 24, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ:DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-tech innovation and AI-driven multimodal digitalization, today announced initial commercial rollout progress in the United States for its acoustic technology-enabled health and wellness care robot solutions, developed in collaboration with Yizhimei Technology Co., Ltd. ("Yizhimei"). According

    3/24/26 9:30:00 AM ET
    $DTSS
    Computer Software: Prepackaged Software
    Technology

    On National Viagra Day, Women Finally Claim Their Turn:

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Every year on March 27th, National Viagra Day celebrates a drug that transformed sexual health for millions of men. Today, Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, is declaring that the conversation is long overdue for an upgrade — and that the future of women's sexual wellness is finally here. Introducing DARE to PLAY™ Sildenafil Cream — the first topical arousal cream clinically studied and developed specifically for women. Where Viagra® was designed for men, DARE to PLAY™ was designed with women in mind

    3/23/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    SEC Form 10-K filed by SWK Holdings Corporation

    10-K - SWK Holdings Corp (0001089907) (Filer)

    3/20/26 4:30:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form 6-K filed by Silicom Ltd

    6-K - SILICOM LTD. (0000916793) (Filer)

    3/18/26 8:15:04 AM ET
    $SILC
    Computer Communications Equipment
    Telecommunications

    Dare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    3/17/26 4:37:30 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G

    2/24/26 7:05:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC